Talphera, Inc. (TLPH)
USD 0.47
(-5.05%)
USD 0.47
(-5.05%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -9.84 Million USD | 42.79% |
| 2022 | -17.2 Million USD | 44.2% |
| 2021 | -30.83 Million USD | 12.46% |
| 2020 | -35.21 Million USD | 32.97% |
| 2019 | -49.03 Million USD | -49.46% |
| 2018 | -34.01 Million USD | 4.84% |
| 2017 | -36.42 Million USD | -23.52% |
| 2016 | -28.98 Million USD | -73.72% |
| 2015 | -16.25 Million USD | 53.2% |
| 2014 | -29.84 Million USD | -505.58% |
| 2013 | -6.07 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -4.23 Million USD | 14.52% |
| 2024 Q2 | -4.27 Million USD | 4.21% |
| 2023 Q2 | -3.92 Million USD | -980.9% |
| 2023 Q1 | 445 Thousand USD | 106.32% |
| 2023 Q3 | -1.41 Million USD | 63.88% |
| 2023 Q4 | -4.51 Million USD | -218.5% |
| 2023 FY | - USD | 42.79% |
| 2022 Q2 | -8.21 Million USD | 4.24% |
| 2022 Q1 | -8.57 Million USD | -11.16% |
| 2022 FY | - USD | 44.2% |
| 2022 Q4 | -7.04 Million USD | -13.47% |
| 2022 Q3 | -6.2 Million USD | 24.39% |
| 2021 Q2 | -9.43 Million USD | -8.56% |
| 2021 Q1 | -8.69 Million USD | 1.92% |
| 2021 FY | - USD | 12.46% |
| 2021 Q4 | -7.71 Million USD | 5.35% |
| 2021 Q3 | -8.15 Million USD | 13.63% |
| 2020 Q1 | -15.36 Million USD | -6.11% |
| 2020 FY | - USD | 32.97% |
| 2020 Q4 | -8.86 Million USD | -3.71% |
| 2020 Q3 | -8.54 Million USD | -34.74% |
| 2020 Q2 | -6.34 Million USD | 58.71% |
| 2019 Q1 | -11.99 Million USD | -10.64% |
| 2019 Q2 | -12.95 Million USD | -8.05% |
| 2019 FY | - USD | -49.46% |
| 2019 Q3 | -13.11 Million USD | -1.24% |
| 2019 Q4 | -14.47 Million USD | -10.39% |
| 2018 Q4 | -10.83 Million USD | -17.97% |
| 2018 Q1 | -8.11 Million USD | -8.98% |
| 2018 Q2 | -7 Million USD | 13.68% |
| 2018 FY | - USD | 4.84% |
| 2018 Q3 | -9.18 Million USD | -31.06% |
| 2017 Q1 | -11.59 Million USD | -74.83% |
| 2017 Q3 | -8.42 Million USD | 11.11% |
| 2017 Q4 | -7.45 Million USD | 11.52% |
| 2017 Q2 | -9.47 Million USD | 18.29% |
| 2017 FY | - USD | -23.52% |
| 2016 Q2 | -7.8 Million USD | 2.56% |
| 2016 Q4 | -6.63 Million USD | 11.1% |
| 2016 Q3 | -7.45 Million USD | 4.43% |
| 2016 Q1 | -8.01 Million USD | -13.55% |
| 2016 FY | - USD | -73.72% |
| 2015 FY | - USD | 53.2% |
| 2015 Q1 | -10.15 Million USD | 10.75% |
| 2015 Q4 | -7.05 Million USD | -192.69% |
| 2015 Q2 | -7.61 Million USD | 25.06% |
| 2015 Q3 | 7.61 Million USD | 199.97% |
| 2014 Q3 | -4.91 Million USD | 59.37% |
| 2014 Q4 | -11.38 Million USD | -131.44% |
| 2014 Q2 | -12.1 Million USD | -44.46% |
| 2014 FY | - USD | -505.58% |
| 2014 Q1 | -8.37 Million USD | -141.61% |
| 2013 FY | - USD | 0.0% |
| 2013 Q1 | -10.42 Million USD | 0.0% |
| 2013 Q2 | -7.62 Million USD | 26.89% |
| 2013 Q3 | -8.15 Million USD | -7.02% |
| 2013 Q4 | 20.13 Million USD | 346.81% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 932.657% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 103.192% |
| Journey Medical Corporation | 1.92 Million USD | 612.337% |
| Dynavax Technologies Corporation | 9.66 Million USD | 201.821% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 93.443% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 93.804% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 106.042% |
| PainReform Ltd. | -9.56 Million USD | -2.853% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -133.673% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -157.346% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -157.346% |
| SCYNEXIS, Inc. | 73.47 Million USD | 113.394% |
| Silver Spike Investment Corp. | 7.34 Million USD | 234.085% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -318.629% |
| Alpha Teknova, Inc. | -25.53 Million USD | 61.463% |
| Alvotech | -484.86 Million USD | 97.97% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 109.003% |
| Bright Green Corporation | - USD | Infinity% |
| Embecta Corp. | 245.4 Million USD | 104.011% |
| Safety Shot Inc | -12.18 Million USD | 19.23% |
| Procaps Group, S.A. | 104.02 Million USD | 109.461% |
| Cosmos Health Inc. | -17.06 Million USD | 42.316% |
| Theratechnologies Inc. | -10.31 Million USD | 4.565% |
| Harrow Health, Inc. | 9.72 Million USD | 201.224% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -117.503% |
| Biofrontera Inc. | -18.45 Million USD | 46.664% |
| DURECT Corporation | -24.68 Million USD | 60.128% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 110.016% |
| Cronos Group Inc. | -72.14 Million USD | 86.359% |
| OptiNose, Inc. | -15.55 Million USD | 36.72% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 98.936% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 72.723% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 137.47% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 127.315% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | -150.921% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -1284.54% |
| Radius Health, Inc. | 38.31 Million USD | 125.69% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -206.121% |
| ProPhase Labs, Inc. | -14.82 Million USD | 33.621% |
| Phibro Animal Health Corporation | 84.6 Million USD | 111.633% |
| Procaps Group S.A. | 104.02 Million USD | 109.461% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -17.153% |
| Viatris Inc. | 3.51 Billion USD | 100.28% |
| Rockwell Medical, Inc. | -4.69 Million USD | -109.672% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -872.53% |
| SIGA Technologies, Inc. | 84.15 Million USD | 111.694% |
| Tilray Brands, Inc. | -72.84 Million USD | 86.489% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 1312.069% |
| Shineco, Inc. | -26.55 Million USD | 62.936% |
| PetIQ, Inc. | 81.48 Million USD | 112.078% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -172.057% |
| Incannex Healthcare Limited | -18.5 Million USD | 46.812% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 102.365% |
| Alimera Sciences, Inc. | 7.27 Million USD | 235.267% |
| Assertio Holdings, Inc. | -222.44 Million USD | 95.576% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -146.627% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 41.431% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 50.866% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 93.4% |
| Hempacco Co., Inc. | -12.77 Million USD | 22.948% |
| Alvotech | -484.86 Million USD | 97.97% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 112.699% |
| Lantheus Holdings, Inc. | 491 Million USD | 102.004% |
| Currenc Group, Inc. | -1.9 Million USD | -417.844% |
| Kamada Ltd. | 21.53 Million USD | 145.704% |
| Indivior PLC | 66 Million USD | 114.912% |
| Evoke Pharma, Inc. | -7.29 Million USD | -34.964% |
| Flora Growth Corp. | -45.87 Million USD | 78.544% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 50.866% |
| Evolus, Inc. | -41.81 Million USD | 76.46% |
| HUTCHMED (China) Limited | 25.52 Million USD | 138.554% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 104.076% |
| Akanda Corp. | -27.73 Million USD | 64.515% |